RGEN Stock — Repligen Corp: Financials

Reported balance	As of	Amount	Source
Current operating lease liabilities	2026-09-30	USD 20,397,000	10-Q filed 2026-10-30
Long-term debt, including current maturities	2026-09-30	USD 555,596,000	10-Q filed 2026-10-30
Noncurrent operating lease liabilities	2026-09-30	USD 116,248,000	10-Q filed 2026-10-30

1.00% Convertible Senior Notes due 2028

Note · Repligen Corporation

Reference: 1.00% Convertible Senior Notes due 2028

Active

Original principal: USD 600,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: Dec 15, 2028

Last reported interest terms: 1% Reported 2023-12-15 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2023-12-15 — 8-K

Issuance · 2023-12-14 Original principal USD 600,000,000 Exact source document Parent 8-K filing · 2023-12-15
On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.

Issuer evidence: On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.

Supporting evidence: The New Notes will mature on December 15, 2028, unless earlier converted, redeemed or repurchased.

Supporting evidence: The New Notes represent senior unsecured obligations of the Company and pay interest semi-annually in arrears on each June 15 and December 15, commencing on June 15, 2024, at a rate of 1.00% per annum.

Supporting evidence: On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.

Supporting evidence: On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Revenue	-2.7%	+15.0%	+24.3%	$813M – $835M*	$805.61M	$738.26M^G	$634.44M^G	$632.36M^G	$801.54M^G	$670.53M^G	$366.26M^G	$270.25M	$194.03M	$141.24M	$104.54M	$83.54M	$63.55M	$68.17M	$62.27M	$27.29M
Cost of Revenue	+0.6%	+17.6%	+25.9%	—	$374.94M	$352.01M	$359.79M	$353.92M	$345.83M	$279.28M	$156.63M	$119.1M	$86.53M	$67.05M	$47.12M	$35.25M	$28.02M	$22.48M	$24.96M	$5.58M
Gross Profit	-5.4%	+13.0%	+23.1%	—	$430.67M	$386.25M	$274.65M	$278.44M	$455.71M	$391.25M	$209.63M	$151.15M	$107.5M	$74.19M	$57.42M	$48.29M	$35.53M	$45.69M	$37.31M	$21.71M
Gross Margin	—	—	—	—	—	52.32%	43.29%	44.03%	56.85%	58.35%	57.23%	55.93%	55.4%	52.53%	54.93%	57.8%	55.9%	67.02%	59.92%	79.55%
Research & Development	+7.2%	+21.8%	+25.2%	—	$57.23M	$54.18M	$43.2M	$42.72M	$43.94M	$34.27M	$20.18M	$19.45M	$15.82M	$8.67M	$7.36M	$5.74M	$5.61M	$7.34M	$10.49M	$12.53M
Selling, General & Administrative	+10.4%	+19.4%	+28.0%	—	$311.98M	$290.51M	$263.37M	$218.58M	$215.83M	$183.87M	$119.62M	$95.61M	$65.69M	$51.51M	$30.85M	$24.7M	$17.15M	$12.7M	$13.23M	$8.02M
Amortization of Intangibles	+13.0%	+19.4%	+37.7%	—	$38.7M	$39.1M	$34.7M	$31.6M	$27.1M	$22.1M	$16.1M	$13.6M	$10.6M	$6.2M	$2.1M	$1.6M	$1.43M	$1.02M	$1.02M	$179K
Depreciation & Amortization	+15.6%	+23.8%	+32.9%	—	$77.9M	$78.75M	$69.67M	$68.56M	$50.99M	$38.45M	$27.07M	$20.87M	$15.78M	$10.51M	$5.33M	$4.59M	$4.02M	$3.11M	$3.51M	$1.67M
Total Costs & Expenses	+5.8%	+18.2%	+25.6%	—	$787.37M	$683.09M	$669.55M	$584.66M	$576.87M	$503.29M	$296.44M	$234.16M	$168.04M	$127.23M	$88.57M	$69.77M	$52.86M	$45.3M	$51.18M	$27.67M
Operating Income	-37.4%	-4.6%	+14.9%	—	$18.24M	$55.17M	-$35.11M	$47.7M	$224.67M	$167.25M	$69.82M	$36.08M	$25.99M	$14.01M	$15.97M	$13.76M	$10.69M	$22.87M	$11.08M	-$374.07K
Operating Margin	—	—	—	—	—	7.47%	-5.53%	7.54%	28.03%	24.94%	19.06%	13.35%	13.39%	9.92%	15.28%	16.48%	16.82%	33.55%	17.8%	-1.37%
EBITDA	-21.4%	+6.7%	+22.0%	—	$96.14M	$133.91M	$34.56M	$116.26M	$275.66M	$205.7M	$96.89M	$56.95M	$41.77M	$24.51M	$21.31M	$18.36M	$14.71M	$25.99M	$14.59M	$1.3M
Interest Expense	+164.5%	+14.8%	+91.8%	—	$22.45M	$21.51M	$20.73M	$1.95M	$1.16M	$11.28M	$10.77M	$9.29M	$6.71M	$6.44M	$3.77M	$32K	$50K	$50K	$56.71K	$26.17K
Other Non-Operating Income	—	—	—	—	-$10.01M	$7.22M	$8.08M	$9M	-$5.53M	-$13.71M	-$10.61M	-$9.93M	-$4.55M	-$6.76M	-$4.28M	-$445K	$188K	-$110K	$26.4K	—
Investment Income (Loss)	—	—	—	—	—	—	—	—	—	—	—	—	$0	$0	$0	$0	$0	$0	$0	—
Pretax Income	-34.2%	+1.0%	+16.6%	—	$8.23M	$62.38M	-$27.04M	$56.71M	$219.14M	$153.54M	$59.22M	$26.15M	$21.44M	$7.25M	$11.69M	$13.42M	$11.14M	$23.01M	$11.27M	-$1.6M
Income Tax	-25.9%	—	+12.7%	—	$20.03M	$13.49M	-$1.52M	$21.11M	$33.18M	$25.25M	-$709K	$4.74M	$4.82M	-$21.11M	$11K	$4.08M	$2.97M	$6.92M	-$2.88M	$15.77K
Net Income	-35.9%	-4.0%	+18.0%	—	-$11.8M	$48.89M	-$25.51M	$35.6M	$185.96M	$128.29M	$59.93M	$21.41M	$16.62M	$28.35M	$11.68M	$9.35M	$8.17M	$16.09M	$14.16M	-$1.61M
Net Margin	—	—	—	—	—	6.62%	-4.02%	5.63%	23.2%	19.13%	16.36%	7.92%	8.56%	20.07%	11.17%	11.19%	12.86%	23.61%	22.73%	—
Comprehensive Income	-16.3%	+5.1%	+31.2%	—	-$33.3M	$98.9M	-$40.24M	$32.18M	$168.45M	$109.32M	$77.04M	$18.28M	$11.09M	$35.74M	$6.5M	$6.55M	$399K	$16.18M	$15.95M	—
EPS (Basic) USD/shares	-36.2%	-5.3%	+12.0%	—	-$0.20	$0.87	-$0.46	$0.64	$3.35	$2.33	$1.14	$0.44	$0.38	$0.74	$0.35	$0.28	$0.25	$0.51	$0.46	$0.00
EPS (Diluted) USD/shares	-35.7%	-5.0%	+11.9%	$2.03 – $2.09*	-$0.20	$0.86^G	-$0.46^G	$0.63^G	$3.24^G	$2.24^G	$1.11^G	$0.44	$0.37	$0.72	$0.34	$0.28	$0.25	$0.50	$0.45	$0.00
Shares Outstanding (Basic Avg) shares	+0.5%	+1.4%	-47.1%	—	—	56.23K	55.94K	55.72K	55.46K	55.02K	52.55K	48.34M	43.77M	38.23M	33.57K	32.88M	32.5M	31.67M	30.91M	30.78M
Shares Outstanding (Diluted Avg) shares	-0.5%	+1.0%	-47.2%	—	—	56.56K	55.94K	56.38K	57.46K	57.26K	53.89K	49.21M	45.47M	39.15M	34.1K	33.58M	33.26M	32.41M	31.25M	30.78M

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Filtration Products	$402,792,000	$372,963,000	$341,379,000	$495,930,000	$403,505,000	$174,851,000	$119,464,000	$90,586,000
Chromatography Products	$153,176,000	$122,810,000	$126,629,000	$131,680,000	$91,037,000	$70,677,000	$60,662,000	$45,326,000
Proteins Products	$97,435,000	$74,425,000	$103,463,000	$114,320,000	$123,707,000	$83,317,000	$69,004,000	$54,375,000
Process Analytics Products	$81,237,000	$59,301,000	$56,820,000	$53,512,000	$48,019,000	$33,346,000	$16,405,000	—
Other Products	$3,320,000	$4,679,000	$3,688,000	$5,741,000	$4,051,000	$3,945,000	$4,562,000	$3,604,000
Royalty	$296,000	$261,000	$383,000	$353,000	$215,000	$124,000	$148,000	$141,000

RGEN · Repligen Corp · Financials

Chart any reported metric, KPI or segment over time — the full statement history lives here

Capital Returned to Shareholders

Debt Profile

Reported debt balances

Covenants

Loans, facilities and notes

1.00% Convertible Senior Notes due 2028

Price & Valuation

Valuation

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

By Product & Service (USD)